IQVIA Holdings Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsIQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.
What they do
IQVIA operates through two segments after a January 1, 2026 reorganization: Commercial Solutions and Research & Development Solutions (R&D Solutions). Commercial Solutions provides mission-critical information, technology solutions, real-world insights and services, including patient and commercial engagement offerings. R&D Solutions primarily serves biopharmaceutical clients with outsourced clinical research and clinical trial services. The company employs approximately 93,000 people in over 100 countries and draws on proprietary healthcare data covering more than 1.2 billion unique non-identified patient records.
Revenue drivers
- Research & Development Solutions — Provides outsourced clinical research and clinical trial services to biopharmaceutical clients. In Q2 2026, revenue was $2,575 million, representing about 59% of total quarterly revenue.
- Commercial Solutions — Delivers information, technology solutions, real-world insights and commercial engagement services. In Q2 2026, revenue was $1,793 million, about 41% of total quarterly revenue.
- R&D Solutions net new bookings and backlog — Bookings drive future revenue conversion. Q2 2026 net new bookings were $3.15 billion, a 1.22x book-to-bill ratio, and contracted backlog was $34.2 billion as of June 30, 2026.
Recent performance
Second-quarter 2026 revenue was $4,368 million, up 8.7% reported and 8.5% at constant currency year-over-year. GAAP net income was $256 million, GAAP diluted EPS was $1.53, adjusted EBITDA was $994 million (up 9.2%), and adjusted diluted EPS was $3.15 (up 12.1%). Commercial Solutions revenue rose 8.6% to $1,793 million, while R&D Solutions revenue rose 8.8% to $2,575 million. R&D Solutions net new bookings were $3.15 billion, up 19% year-over-year, and last-twelve-months net new bookings were $11.3 billion, up 13%. For the first half of 2026, revenue was $8,519 million, up 8.6% reported, with adjusted diluted EPS of $6.04, up 9.8%.
Strategy
Effective January 1, 2026, IQVIA simplified its organizational model from three segments to two: Commercial Solutions (which absorbed the former Contract Sales & Medical Solutions segment and was renamed from Technology & Analytics Solutions) and R&D Solutions (which absorbed Real-World Late Phase and certain other real-world offerings). The company states this aligns with industry evolution and its updated operating model. IQVIA continues to pursue strategic business combinations, investing $1,714 million net of cash in acquisitions during 2025 across all prior segments. It emphasizes responsible AI use through its IQVIA Connected Intelligence platform and Healthcare-grade AI capabilities. The company also repurchased $398 million of common stock in Q2 2026, with $2,819 million of authorization remaining as of June 30, 2026.
Risks
- Client cautiousness and contract delays — IQVIA's R&D Solutions segment was impacted by client cautiousness in 2025, slowing customer decision-making due to macroeconomic factors.
- Contract termination and pricing risk — Most contracts may be terminated on short notice, and the company may underprice contracts, overrun cost estimates or fail to receive approval for change orders.
- Data supplier dependence — IQVIA depends on third parties for data and support services, and suppliers might restrict or refuse to license data, which could impair service offerings.
- Integration and growth investment risk — Failure to successfully identify, acquire and integrate businesses, services and technologies could adversely affect results and financial condition.
Outlook
Management raised full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted EPS following strong Q2 results. IQVIA expects approximately $9.2 billion of its $34.2 billion R&D contracted backlog to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year. CEO Ari Bousbib cited favorable forward-looking indicators across both segments and pointed to sustained momentum for the balance of 2026 and into 2027. The company also noted a strengthening market environment and increased AI solution adoption.